Trial Comparing Ablation With Medical Therapy in Patients With Ventricular Tachycardia (VeTAMed)
This study has been withdrawn prior to enrollment.
(Low Enrolment)
Sponsor:
Newmarket Electrophysiology Research Group Inc
Collaborator:
Biosense Webster, Inc.
Information provided by (Responsible Party):
Newmarket Electrophysiology Research Group Inc
ClinicalTrials.gov Identifier:
NCT01798277
First received: February 20, 2013
Last updated: January 26, 2015
Last verified: January 2015
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study aims to compare antiarrhythmic drug therapy with catheter ablation using the SmartTOUCH catheter (Biosense Webster Inc.) as treatment for patients with ventricular tachycardia and coronary artery disease
| Condition | Intervention | Phase |
|---|---|---|
|
Ventricular Tachycardia Coronary Artery Disease |
Procedure: Catheter Ablation Drug: Medical therapy (sotalol or amiodarone) |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Ablation Versus Medical Therapy in Patients With Coronary Artery Disease and Sustained Ventricular Tachycardia Randomized Trial (VeTAMed) |
Resource links provided by NLM:
Genetics Home Reference related topics:
catecholaminergic polymorphic ventricular tachycardia
familial atrial fibrillation
MedlinePlus related topics:
Coronary Artery Disease
U.S. FDA Resources
Further study details as provided by Newmarket Electrophysiology Research Group Inc:
Primary Outcome Measures:
- Recurrence of Ventricular Tachycardia [ Time Frame: 1 year ] [ Designated as safety issue: No ]Number of any appropriate ATPs/shocks and/or presentations of sustained (>30sec) VT on Holter or ECG recording at 3, 6, 9 and 12 months after intervention
Secondary Outcome Measures:
- Time to First Shock/ATP for VT or to First Presentation of Sustained VT [ Time Frame: 1 year ] [ Designated as safety issue: No ]Change in time to first ATP/shock or presentation of sustained (>30sec) VT on Holter or ECG recording at 3, 6, 9 and 12 months after intervention
- Total mortality [ Time Frame: 1 year ] [ Designated as safety issue: No ]Change in mortality status at 3, 6, 9 and 12 months after intervention
- Sudden cardiac death [ Time Frame: 1 year ] [ Designated as safety issue: No ]Change in sudden cardiac death status at 3, 6, 9 and 12 months after intervention
- Syncope [ Time Frame: 1 year ] [ Designated as safety issue: No ]Change in syncope status at 3, 6, 9 and 12 months after intervention
- Number of hospitalizations [ Time Frame: 1 year ] [ Designated as safety issue: No ]Change in number of hospitalizations at 3, 6, 9 and 12 months after intervention
- QOL measures [ Time Frame: 1 year ] [ Designated as safety issue: No ]Change in QOL measures at 6 and 12 months after intervention
| Enrollment: | 0 |
| Study Start Date: | April 2013 |
| Estimated Study Completion Date: | December 2015 |
| Estimated Primary Completion Date: | June 2015 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Catheter Ablation
Radiofrequency ablation procedure
|
Procedure: Catheter Ablation
Catheter ablation of ventricular tachycardia will employ three-dimensional mapping Fast Anatomical Mapping or CARTOSOUND technology (Biosense Webster Inc.), and the Thermocool Navistar catheter (Biosense Webster Inc.).
Other Names:
|
|
Active Comparator: Medical therapy
Antiarrhythmic drug therapy will include amiodarone or sotalol. Which antiarrhythmic drug will prescribed per patient depends on the observing physician.
|
Drug: Medical therapy (sotalol or amiodarone)
Patients will be tiered to one of two possible antiarrhythmic drugs (sotalol or amiodarone).
Other Name: Sotalol - Betapace, Betapace AF, Sotalex, Sotacor
|
Detailed Description:
This is a multicenter, randomized prospective cohort study to compare the impact of catheter ablation with antiarrhythmic drug therapy for treating patients with sustained ventricular tachycardia (VT) and coronary artery disease. Patients that meet all inclusion criteria and no exclusion criteria will be recruited to the study cohort. After baseline measurements are taken, patients will be randomized in a 2:1 fashion to either undergo radiofrequency catheter ablation or receive antiarrhythmic drug therapy (amiodarone or sotalol). The in-clinic appointments include: enrollment, baseline, intervention, and follow-up every three months for one year post-ablation. At each follow-up visit, electrogram (ECG) and Holter monitoring tests will be performed to measure any episodes of ventricular tachyarrhythmia. Furthermore, interrogation of the patient's implantable cardioverter defibrillator (ICD) will be performed at all follow-up visits to detect any episodes of ventricular tachyarrhythmia that required antitachycardia pacing (ATP) or shocks.
Eligibility| Ages Eligible for Study: | 18 Years to 85 Years (Adult, Senior) |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Sustained monomorphic VT (>30 seconds, or requiring appropriate ICD therapy in patients with ICDs)
- Documented ischemic heart disease with no further options for revascularization
- Ability and willingness to give written informed consent to participate in the trial
Exclusion Criteria:
- VT in the setting of metabolic abnormalities or acute ischemia if coronary lesions suitable for revascularization are identified.
- Acute ischemia with eligibility for revascularization
- Significant peripheral arterial disease preventing transvascular access to the left ventricle.
- Patients with arrhythmogenic right ventricular cardiomyopathy (ARVC), hypertrophic cardiomyopathy, Brugada syndrome, Long QT syndromes, dilated cardiomyopathy
- Prior long term therapy with a Class III or Class IC antiarrhythmic agent (longer than 2 weeks)
- Patient is or may be potentially pregnant
- Patient has a mechanical heart valve
- Myocardial infarction within the past 90 days
- Stroke within the past 90 days
- New York Heart Association (NYHA) functional class IV
- Hemorrhagic manifestations, bleeding diathesis, or impairment of hemostasis
- Lesions at risk of clinically significant bleeding (e.g., extensive cerebral infarction within the last 6 months, active peptic ulcer disease with recent bleeding)
- Prior VT ablation procedure
- Contraindication or allergy to contrast media, routine procedural medications or catheter materials
- Contraindications to an interventional procedure
- Life expectancy is less than 6 months
- Incessant or multiple episodes of VT requiring immediate therapy with medications or ablation
- Untreated hypothyroidism or hyperthyroidism (euthyroid or thyroid hrt is acceptable)
- Current enrolment in another investigational drug or device study
- There are other conditions present that the investigator feels would be problematic or would restrict or limit the participation for the patient for the entire study period
- Absolute contraindication to the use of heparin or warfarin
- Documented intra-arterial thrombus, ventricular thrombus, (less than 6 months after detection of thrombus), tumor or other abnormality that precludes catheter introduction
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01798277
Please refer to this study by its ClinicalTrials.gov identifier: NCT01798277
Sponsors and Collaborators
Newmarket Electrophysiology Research Group Inc
Biosense Webster, Inc.
Investigators
| Principal Investigator: | Yaariv Khaykin, MD | Newmarket Electrophysiology Research Group |
More Information
| Responsible Party: | Newmarket Electrophysiology Research Group Inc |
| ClinicalTrials.gov Identifier: | NCT01798277 History of Changes |
| Other Study ID Numbers: | NERG-02 |
| Study First Received: | February 20, 2013 |
| Last Updated: | January 26, 2015 |
| Health Authority: | Canada: Ethics Review Committee |
Keywords provided by Newmarket Electrophysiology Research Group Inc:
|
Keywords provided by Newmarket Electrophysiology Research Group Inc: Ventricular tachycardia Ventricular tachyarrhythmia Ablation Coronary artery disease Ischemic heart disease Amiodarone Sotalol Anti-Arrhythmia Agents |
Therapeutic Uses Pharmacologic Actions Additional relevant MeSH terms: Atrial Fibrillation Arrhythmias, Cardiac Heart Diseases Cardiovascular Diseases Pathologic Processes Catheter Ablation, Radiofrequency |
Additional relevant MeSH terms:
|
Coronary Artery Disease Myocardial Ischemia Coronary Disease Tachycardia Tachycardia, Ventricular Heart Diseases Cardiovascular Diseases Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases Arrhythmias, Cardiac Pathologic Processes Amiodarone Sotalol Anti-Arrhythmia Agents |
Vasodilator Agents Potassium Channel Blockers Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Sodium Channel Blockers Cytochrome P-450 CYP1A2 Inhibitors Cytochrome P-450 Enzyme Inhibitors Enzyme Inhibitors Cytochrome P-450 CYP2C9 Inhibitors Cytochrome P-450 CYP2D6 Inhibitors Cytochrome P-450 CYP3A Inhibitors Adrenergic beta-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents |
ClinicalTrials.gov processed this record on September 27, 2016